Open AccessP1239: TISLELIZUMAB, A PD‐1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T‐ AND NK‐CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY
Author(s) -
Bachy E.,
Savage K. J.,
Huang H.,
Kwong Y. L.,
Gritti G.,
Zhang Q.,
Liberati A. M.,
Cao J.,
Yang H.,
Hao S.,
Hu J.,
Zhou K.,
Russo F.,
Zhang H.,
Sang W.,
Ji J.,
Ferreri A. J. M.,
Damaj G. L.,
Liu H.,
Zhang W.,
Ke X.,
Ghiggi C.,
Huang S.,
Li X.,
Yao H.,
Paik J.,
Novotny W.,
Zhou W.,
Zhu H.,
Huang J.,
Zinzani P. L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847820.72232.2a
Subject(s) - medicine , lymphoma , cohort , anaplastic large cell lymphoma , refractory (planetary science) , oncology , clinical endpoint , gastroenterology , peripheral t cell lymphoma , t cell , immunology , clinical trial , immune system , astrobiology , physics